Target joint resolution with emicizumab prophylaxis by study
| . | HAVEN 1 (n = 113) . | HAVEN 2 (n = 88) . | HAVEN 3 (n = 151) . | HAVEN 4 (n = 48) . | Total (N = 400) . |
|---|---|---|---|---|---|
| Evaluable participants with target joints at baseline* | 68 (60.2) | 33 (37.5) | 96 (63.6) | 29 (60.4) | 226 (56.5) |
| Target joints at baseline among evaluable participants, n | 159 | 57 | 237 | 77 | 530 |
| Proportion of evaluable participants with no spontaneous or traumatic bleeds in target joints | 63 (92.6) | 32 (97.0) | 81 (84.4) | 26 (89.7) | 202 (89.4) |
| Target joints with 0 spontaneous or traumatic bleeds among target joints from evaluable participants | 154 (96.8) | 56 (98.2) | 218 (92.0) | 70 (90.9) | 498 (94.0) |
| Target joints resolved among target joints from evaluable participants† | 155 (97.5) | 56 (98.2) | 223 (94.1) | 70 (90.9) | 504 (95.1) |
| Target joints resolved among target joints from evaluable participants‡ | 156 (98.1) | 57 (100) | 234 (98.7) | 76 (98.7) | 524 (98.9) |
| . | HAVEN 1 (n = 113) . | HAVEN 2 (n = 88) . | HAVEN 3 (n = 151) . | HAVEN 4 (n = 48) . | Total (N = 400) . |
|---|---|---|---|---|---|
| Evaluable participants with target joints at baseline* | 68 (60.2) | 33 (37.5) | 96 (63.6) | 29 (60.4) | 226 (56.5) |
| Target joints at baseline among evaluable participants, n | 159 | 57 | 237 | 77 | 530 |
| Proportion of evaluable participants with no spontaneous or traumatic bleeds in target joints | 63 (92.6) | 32 (97.0) | 81 (84.4) | 26 (89.7) | 202 (89.4) |
| Target joints with 0 spontaneous or traumatic bleeds among target joints from evaluable participants | 154 (96.8) | 56 (98.2) | 218 (92.0) | 70 (90.9) | 498 (94.0) |
| Target joints resolved among target joints from evaluable participants† | 155 (97.5) | 56 (98.2) | 223 (94.1) | 70 (90.9) | 504 (95.1) |
| Target joints resolved among target joints from evaluable participants‡ | 156 (98.1) | 57 (100) | 234 (98.7) | 76 (98.7) | 524 (98.9) |
Unless otherwise stated, data are n (%).
Evaluable participants are those with ≥52 weeks of emicizumab prophylaxis (up to uptitration, if applicable). Of those, participants with target joints at baseline are shown.
Target joint resolution was defined as ≤2 spontaneous or traumatic bleeding events in a 52-week period in a joint previously defined as a target joint.
Alternative target joint resolution definition: ≤2 spontaneous bleeding events in a 52-week period in a joint previously defined as a target joint.